Status:
WITHDRAWN
Mindfulness to Mitigate the Effect of Anxiety-depression-fear in Chronic Obstructive Pulmonary Disease (COPD)
Lead Sponsor:
Mayo Clinic
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
40+ years
Phase:
NA
Brief Summary
People with COPD have a greater risk for symptoms of depression, anxiety, and fear of breathlessness. Those emotions are independently associated with lower physical activity, poorer quality of life, ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Lung disease diagnosis
- Demonstrated competence in proposed technology
- Current or past smoking status
- Patient Health Questionnaire-2 (PHQ-2) or Generalized Anxiety Disorder scale (GAD-2) score \>2 points or answering yes to a validated question of fear of being breathless ("Do you experience fear, or panic when you have difficulty getting your breath a good bit of the time?")
- Exclusion criteria:
- High likelihood of non-compliance or low confidence using the technology
- Patients currently in pulmonary rehabilitation
- Inability to walk
- Prescribed antidepressant or antianxiety medication within last month
- Documented substance abuse
- Cognitive impairment as defined by the Mini-Mental test score \< 24.
Exclusion
Key Trial Info
Start Date :
April 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 31 2017
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03385317
Start Date
April 1 2016
End Date
October 31 2017
Last Update
December 28 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55902